

Renasight Kidney gene panel


FEATURED CASE STUDY: Real-world cfDNA in the Era of COVID-19



Monitoring transplant patients during the COVID-19 resurgence has become more difficult and risky.

This case study¹ highlights a transplant center's evaluation of kidney recipients diagnosed with COVID-19 aimed to:

- Determine if background cfDNA levels were elevated in severe COVID-19 cases •
- Assess if background cfDNA levels correlated with COVID-19 severity and outcome
- Map kinetics of background cfDNA in patients as they recover



Key Takeaway: Four of the nine patients with COVID-19 exhibited very elevated levels of background cfDNA. In both cases of severe COVID infection that led to death, background cfDNA levels were markedly elevated compared to those who recovered. In both surviving patients with elevated background cfDNA, background levels returned to baseline by 75 days post-infection.

Exploratory Questions:

- 1. Do you have transplant patients with COVID-19 who might benefit from Prospera?
- 2. How have you managed immunosuppressive therapies in your kidney transplant patients who have COVID-19?
- 3. What might you do differently after reading this case study?

201 Industrial Road, Suite 410 | San Carlos, CA 94070 | Main +1 650.249.9090 | Fax 1.650.730.2272 | natera.com

The test described has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485 certified, and CLIA certified. © 2021 Natera, Inc. All Rights Reserved. OH_Community_bulletin2_cfDNA_Postcard_030121_NAT-8020417





Prospera™ Transplant assessment Renasight[™] Kidney gene panel

A Call for Stories:

Share your learnings with our community

Natera wants to thank all the healthcare professionals who have been on the frontlines of this crisis. Your dedication, determination, grit, resilience, and sacrifice over the last few months have been inspiring and invaluable to our community.

We extend our call for stories, research, and experiences to our transplant and nephrology partners so we can continue to learn together and improve patients' lives during these uncertain times.

Please contact prospera@natera.com to discuss with the Natera Clinical Team.

201 Industrial Road, Suite 410 | San Carlos, CA 94070 | Main +1 650.249.9090 | Fax 1.650.730.2272 | natera.com

The test described has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485 certified, and CLIA certified. © 2021 Natera, Inc. All Rights Reserved. OH_Community_bulletin2_cfDNA_Postcard_030121_NAT-8020417

